
Abbott Laboratories
ABT · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $188 bn
- Div. yield
- 2,0%
- Year to date
- −13,4%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
2 ✓ · 2 — · 5 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 40,0 | 29,7 | 25,1 |
| Forward P/E | 18,1 | — | 16,2 |
| PEG | 4,7 | — | 2,2 |
| P/S | 3,9 | 4,7 | 2,2 |
| EV/EBITDA | 23,9 | 22,8 | 17,3 |
| P/FCF | 27,8 | — | 19,5 |
| P/B | 3,7 | 4,7 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 33 analysts
- Buy
- 26
- Hold
- 7
- Sell
- 0
Beat the EPS forecast in 1 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 1,43 | 1,42 | Down −0,7% |
| Q2 2026 | 1,29 | 1,31 | Up +1,4% |
| Q1 2026 | 1,16 | 1,15 | Down −0,5% |
| Q4 2025 | 1,51 | 1,50 | Down −0,7% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13,0 bn | 12,6 bn | 11,2 bn | 11,5 bn | 11,4 bn | 11,1 bn | 10,4 bn | 11,0 bn | 10,6 bn | 10,4 bn | 9,96 bn | 10,2 bn |
| EPS | 0,53 | 0,53 | 0,61 | 1,02 | 0,94 | 1,01 | 0,76 | 5,26 | 0,94 | 0,74 | 0,70 | 0,91 |
| Margin | 7,1% | 7,4% | 9,6% | 15,5% | 14,5% | 16,0% | 12,8% | 84,1% | 15,5% | 12,5% | 12,3% | 15,6% |
| FCF | 1,22 bn | 1,99 bn | 916 m | 2,63 bn | 2,29 bn | 1,55 bn | 933 m | 2,15 bn | 2,15 bn | 1,43 bn | 627 m | 2,28 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $4,40 m (4 people), sales $47,9 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| moreland mary k5 Nov 2026 · sale | $406 000 | 3 500 | $116,00 |
| mccoy john a. jr.2 Sep 2026 · sale | $2 958 | 27 | $109,54 |
| ford robert b25 Aug 2026 · sale | $20,9 m | 180 297 | $116,19 |
| ford robert b25 Aug 2026 · sale | $25,3 m | 218 535 | $115,57 |
| morrone louis h.11 Aug 2026 · sale | $642 506 | 5 850 | $109,83 |
| stratton john g7 May 2026 · open-market purchase | $173 640 | 2 000 | $86,82 |
| starks daniel j27 Apr 2026 · open-market purchase | $926 537 | 10 000 | $92,65 |
| boudreau philip p23 Apr 2026 · open-market purchase | $201 300 | 2 200 | $91,50 |
| cushman elizabeth c.2 Mar 2026 · sale | $30 398 | 263 | $115,58 |
| shroff eric2 Mar 2026 · sale | $81 946 | 709 | $115,58 |
| morrone louis h.2 Mar 2026 · sale | $132 224 | 1 144 | $115,58 |
| moreland mary k2 Mar 2026 · sale | $70 851 | 613 | $115,58 |
| mccoy john a. jr.2 Mar 2026 · sale | $67 614 | 585 | $115,58 |
| salvadori daniel gesua sive2 Mar 2026 · sale | $102 288 | 885 | $115,58 |
| starks daniel j4 Feb 2026 · open-market purchase | $545 239 | 5 033 | $108,33 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 1 Mar 1937
- Website
- www.abbott.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
ISRGIntuitive Surgical | $437,75 | 83★★★★★★★★★would consider | 52,0 | +20,5% | 25,5% |
MDTMedtronic | $102,88 | 78★★★★★★★★★would consider | 25,1 | +9,8% | 13,9% |
MCKMcKesson | $1 105,04 | 72★★★★★★★★★would consider | 27,3 | +8,2% | 1,1% |
SYKStryker Corporation | $310,72 | 72★★★★★★★★★would consider | 33,0 | +7,9% | 13,8% |
CVSCVS Health | $88,59 | 83★★★★★★★★★would consider | 10,4 | +6,7% | 2,6% |
Ratio — a score by our methodology, not an investment recommendation.




